Bristol Myers: breakthrough in melanoma survival
(CercleFinance.com) - Bristol Myers Squibb today announced that the Phase 3 CheckMate trial evaluating Opdivo (nivolumab) as a single agent in patients with fully resected stage IIB/C melanoma demonstrated a statistically significant and clinically meaningful benefit in terms of relapse-free survival.
CheckMate -76K is part of BMS' development program investigating Opdivo and Opdivo-based combinations in early stage cancer, which currently covers seven tumour types.
It said that the results of the CheckMate -76K study represent a significant advance for patients with stage IIB/C melanoma and an extension of our legacy in the treatment of melanoma.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
CheckMate -76K is part of BMS' development program investigating Opdivo and Opdivo-based combinations in early stage cancer, which currently covers seven tumour types.
It said that the results of the CheckMate -76K study represent a significant advance for patients with stage IIB/C melanoma and an extension of our legacy in the treatment of melanoma.
Copyright (c) 2022 CercleFinance.com. All rights reserved.